Ovarian/Uterine Cancer

SEQ-1274 Drug Platform

A novel molecule class to inhibit ovarian and other cancer cell growth

SEQ-1274 is a chemically synthesized analogue of a new compound discovered using our platform technology.1 We are developing this and other novel small molecules from this platform as a potential treatment for serious, high-grade ovarian and potentially other cancers.

1. "Isolation and Identification of the Novel Tubulin Polymerization Inhibitor Bifidenone," R.B. Williams, et al,Journal of Natural Products, Article ASAP, DOI: 10.1021/acs.jnatprod.6b00893).

Indication or Program Preclinical Phase 1 Phase 2 Phase 2/3 Market

SEQ-1274 drug platform

Ovarian and Other Cancers

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 2/3 Phase not started
Market Phase not started

Ovarian cancer market overview


Estimated number of women who will be diagnosed in the U.S.


Estimated number of deaths that will occur due to ovarian cancer


Overall 5-year survival rate for ovarian cancer


Source: American Cancer Society. Cancer Facts & Figures 2022.

How it works

An inside look at SEQ-1274

SEQ-1274 is a novel microtubule inhibitor that binds to the colchicine-binding site on tubulin, a protein and main component for forming microtubules (hollow fibers that act as skeletal structures for living cells).

SEQ-1274 and analogs are potently active against over 50 human cancer cell lines (including ovarian, lung, breast, colon, central nervous system (CNS), melanoma, prostate, renal, and uterine), including several taxane-resistant cell lines. It is 5-1000 times more active than paclitaxel in a number of these cell lines.

Preclinical studies

SEQ-1274 compared to paclitaxel (taxane) in animal tumor models

SEQ-1274 has demonstrated efficacy in animal tumor models performed at four independent laboratories. Washington University researchers led by Dr. Katherine C. Fuh recently examined the potential of SEQ-1274 in the arsenal against ovarian and uterine cancers. The group compared SEQ-1274 to paclitaxel, a microtubule inhibitor, and found that SEQ-1274 was more active against ovarian and uterine cancer cell lines and that SEQ-1274 can decrease the expression of AXL, a protein contributing to paclitaxel resistance.

Mills, K. A., Roach, S. T., Quinn, J. M., Guo, L., Beck, H. M., Lomonosova, E., Ilivicky, A. R., Starks, C. M., Lawrence, J. A., Hagemann, A. R., McCourt, C., Thaker, P. H., Powell, M. A., Mutch, D. G., & Fuh, K. C. (2018). SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. Gynecologic Oncology, 151(2), 337–344. https://doi.org/10.1016/j.ygyno.2018.08.008

Development & milestones

SEQ-1274 analogs for ovarian cancer timeline

Optimization for IND-enabling preclinical safety studies will be completed in 2024, and we anticipate entering clinical trials in 2025.

View latest news


For recurrent UTIs

Our lead program, SEQ-400, is a FimH vaccine for the prevention of recurrent urinary tract infections (UTIs).

Novel Small Molecule Drug Platform

For lung infections in cystic fibrosis patients

Novel compounds that target spreading bacterial biofilms that negatively impact lung functions.

Research & publications

Sequoia’s research and development studies and programs have been published in more than 50 peer-reviewed scientific publications. We invite you to learn more about our science.

View publications